logo
  

BATM Advanced Communications Annual Profit Rises

BATM Advanced Communications Limited (BVC.L) on Monday said its profit before tax increased 87.5% for the full year to $24.93 million from $13.3 million a year ago.

The company posted profit of $14.34 million or 3.23 cents per share for the year, higher than $9.79 million or 2.21 cents per share last year.

Reported revenue was $140.04 million for the full year, a decline from $183.57 million in the prior year.

However, revenue from ongoing operations increased 18% to $132.8 million from $112.6 million in the previous year, helped by revenue growth in all segments.

EBITDA, or earnings before interest, taxes, depreciation, and amortization, from ongoing operations increased by 138.8% to $15.7 million from $6.6 million a year ago.

On a reported basis, EBITDA grew 50.4% year-over-year to $29.6 million.

Looking forward, BATM said, "The Group entered the new year with a substantially higher backlog for ongoing operations than at the same point the prior year and is continuing to experience sustained momentum across the business. Accordingly, the Group remains on track to deliver significant growth for full year 2022 in line with market expectations."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT